Protective effects of fucoidan against hyperoxic lung injury via the ERK signaling pathway

MINGHAO NIE, YAN WANG, YANHONG LU, YING YUAN, YINGYING LIU and XIURONG LI

Department of Pathology, Heilongjiang Provincial Hospital, Harbin, Heilongjiang 150036, P.R. China

Received June 2, 2016; Accepted May 8, 2017

DOI: 10.3892/mmr.2017.8022

Abstract. High oxygen mechanical ventilation is widely used to treat various lung diseases; however, it may result in hyperoxia, which induces inflammation and lung injury. Fucoidan is an extract of the seaweed Fucus vesiculosus, which has previously been reported to exert effects against diabetic nephropathy. The present study is the first, to the best of our knowledge, to investigate the protective effects of fucoidan against hyperoxic lung injury. Balb/c mice were ventilated with 100% oxygen, with or without the atomization inhalation of fucoidan, for 36 h. Hyperoxia reduced the body weight and increased the relative lung weight of the mice. In addition, cell quantity and differentiation were determined using a hemocytometer, hyperoxia increased the total number of cells, and the number of macrophages, neutrophils and lymphocytes in the bronchoalveolar lavage fluid. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) demonstrated that hyperoxia also increased the mRNA expression levels of cluster of differentiation (CD)68, F4/80, CD64 and CD19 in lung tissue, and induced lung morphological alterations. Furthermore, western blotting assay demonstrated that hyperoxia increased the expression levels of interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)-α, and the phosphorylation of extracellular signal-regulated kinase (ERK)1/2. These findings suggest that fucoidan may attenuate hyperoxic lung injury via the ERK1/2 signaling pathway.

Introduction

High oxygen mechanical ventilation is widely used as a clinical therapy to treat various diseases (1), including conditions associated with serious respiratory failure, such as hyperoxemia and acute respiratory distress syndrome (ARDS) (2). However, as suggested in a previous report (3), exposure to high levels of oxygen for prolonged periods of time may lead to inflammation and lung injury (4). Reactive oxygen species (ROS) are generated under hyperoxic conditions and result in oxidative damage and inflammatory response in the injured lung tissue (5). Inflammatory cells accumulating in the lung also generate ROS (6). Currently, antioxidants and antiallergic drugs are used to protect the lung against hyperoxic lung injury (7,8). However, these drugs often bring side effects. Therefore, the development of a therapeutic strategy that alleviates hyperoxia-induced lung injury without side effects is required.

Interest in the biological activities of marine organisms has intensified in the last few years (9). Fucoidan, the chemical structure of which is presented in Fig. 1A, is an extract of the seaweed Fucus vesiculosus, which has been widely investigated and has been reported to serve an important role in cancer (10) and inflammation (11). Fucoidan exhibits antioxidant, anticancer and anti-inflammatory activities (12), and our previous study demonstrated its effects against diabetic nephropathy (13). The present study aimed to determine whether fucoidan may attenuate or prevent hyperoxia-induced lung injury.

Activation of extracellular signal-regulated kinase (ERK) 1/2 has been reported to be associated with defense signaling against injury (14). High oxygen mechanical ventilation may induce the phosphorylation of ERK1/2, and the secretion of chemokines and cytokines, such as interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)-α (15), finally leading to inflammatory cell infiltration (16) and lung injury. The present study indicated that hyperoxia induced inflammation and morphological alterations in mouse lung tissue. Conversely, atomization inhalation of fucoidan reduced hyperoxia-induced inflammation, morphological alterations, the expression levels of IL-1, IL-6 and TNF-α, and the phosphorylation of ERK1/2. These findings suggest that fucoidan may attenuate hyperoxic lung injury via the ERK1/2 signaling pathway, thus indicating a novel therapeutic strategy for the alleviation of hyperoxia-induced lung injury.

Key words: fucoidan, hyperoxic lung injury, interleukin-1, interleukin-6, tumor necrosis factor-α, extracellular signal-regulated kinase 1/2

Correspondence to: Professor Xiurong Li, Department of Pathology, Heilongjiang Provincial Hospital, 82 Zhongshan Road, Harbin, Heilongjiang 150036, P.R. China

E-mail: lixiurong8817@sina.com
Materials and methods

Animals. The present study was approved by the Ethics Committee of Harbin Medical University (Harbin, China). The experiments were conducted at the Animal Experimental Center of Harbin Medical University in accordance with the Animal Experiment Guidelines from Harbin Medical University. Balb/c mice, not limited to gender (male/female ratio was 1:1), were housed in a controlled environment, with a temperature of 24±1˚C, and a 12-h light/dark cycle. Briefly, Balb/c mice (age, 6-8 weeks; Institute of Laboratory Animal Sciences, Shanghai, China) were fed normal chow and water ad libitum. The mice (n=5-6 per group) were ventilated with 100% oxygen, with or without atomization inhalation of fucoidan (100 µg/ml; Kanehide Bio Co., Ltd., Okinawa, Japan), for 36 h, according to previous studies (17,18). Untreated mice were used as control. Following exposure to 100% oxygen, the body weight and relative lung weight of Balb/c mice were measured before and after sacrifice respectively, and lung tissue and bronchoalveolar lavage fluid (BALF) samples were collected for further experimentation.

Preparation of BALF. The lungs were washed with 0.5 ml sterile saline four times through a 21G flat syringe needle cannulated 0.7 cm into the trachea. The BALF recovered from each mouse was subsequently used for quantitative cell counting. Cell quantity and differentiation were determined using a hemocytometer (Countess® II Automated Cell Counter; AMQAX1000; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for >500 cells placed on cytocentrifuge slides and stained with Wright-Giemsa (19). The total cell number was counted by the Automated Cell Counter, and the macrophages, neutrophils and lymphocytes with Giemsa staining were confirmed and counted under a microscope (Olympus Corporation, Tokyo, Japan) at a magnification of x100. A 100 µl aliquot of BALF was collected, after total cell counting, the remainder was immediately centrifuged at 1,000 x g for 10 min. Macrophages were isolated from the BALF. The BALF supernatants were stored at -80˚C for cytokine and chemokine analyses.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from the lung tissue by TRIzol (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and the relative mRNA expression levels of cluster of differentiation (CD)68, CD163, 80, CD64 and CD19 were normalized to 18S expression. The morphometric analysis was performed using ImageJ software version 1.60 (National Institutes of Health, Bethesda, MD, USA) (23).

Enzyme-linked immunosorbent assay (ELISA). BALF and homogenized lung tissue were collected and underwent IL-1, IL-6 and TNF-α assays using respective mouse ELISA kits (RAB0275, RAB0309 and GERPN2718; Merck KGaA). The ELISA plates were incubated with 100 µl capture antibody per well at 4˚C overnight. After appropriate washing by the washing buffer from the kits, 200 µl assay dilution buffer was added per well for blocking at room temperature for 1 h. Serial dilutions of standards and samples were added to each well and were incubated at 4˚C overnight. Avidin-horseradish peroxidase (HRP) was added following incubation with the detection antibody for 30 min at room temperature, and the samples were further incubated at room temperature for another 30 min. Subsequently, the 3,3′,5,5′-tetramethylbenzidine substrate was added, and following incubation for 15 min at room temperature, NH₄SO₄ was added to terminate the reaction and absorbance was measured at 450 nm using an ELISA reader (MTP-800 microplate reader; Corona Electric Co., Ltd., Tokyo, Japan).

Western blotting. According to method described by Laemmli (24) for western blotting, electrophoresis was performed using a vertical slab gel containing 12% polyacrylamide. Lung tissues were ground and lysed with radio-immunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China). The concentration of proteins extracted from lung tissues was determined by Gene Spec III from Hitachi Genetic Systems (MiraiBio Group, South San Francisco, CA, USA). PCR results were analyzed by 2^ΔΔCq method (21).

Morphometric analysis. As previously described, (22), lung tissues were fixed in formalin (Sigma-Aldrich; Merck KGaA), cleared in xylene (Sigma-Aldrich; Merck KGaA) and embedded in paraffin. The paraffin-embedded lung tissue samples were examined by conventional light microscopic examination; 5 µm sections were stained with hematoxylin and eosin, and were assessed in a blinded manner. An automatic microscope (Provis AX-70) with a camera (Olympus Corporation, Tokyo, Japan) was used to capture the microscopic images of the lung samples. The morphometric analysis was performed using ImageJ software version 1.60 (National Institutes of Health, Bethesda, MD, USA) (23).

Preparation of BALF. The lungs were washed with 0.5 ml sterile saline four times through a 21G flat syringe needle cannulated 0.7 cm into the trachea. The BALF recovered from each mouse was subsequently used for quantitative cell counting. Cell quantity and differentiation were determined using a hemocytometer (Countess® II Automated Cell Counter; AMQAX1000; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for >500 cells placed on cytocentrifuge slides and stained with Wright-Giemsa (19). The total cell number was counted by the Automated Cell Counter, and the macrophages, neutrophils and lymphocytes with Giemsa staining were confirmed and counted under a microscope (Olympus Corporation, Tokyo, Japan) at a magnification of x100. A 100 µl aliquot of BALF was collected, after total cell counting, the remainder was immediately centrifuged at 1,000 x g for 10 min. Macrophages were isolated from the BALF. The BALF supernatants were stored at -80˚C for cytokine and chemokine analyses.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from the lung tissue by TRIzol (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and the relative mRNA expression levels of cluster of differentiation (CD)68, F4/80, CD64 and CD19 were normalized to 18S expression. The morphometric analysis was performed using ImageJ software version 1.60 (National Institutes of Health, Bethesda, MD, USA) (23).

Enzyme-linked immunosorbent assay (ELISA). BALF and homogenized lung tissue were collected and underwent IL-1, IL-6 and TNF-α assays using respective mouse ELISA kits (RAB0275, RAB0309 and GERPN2718; Merck KGaA). The ELISA plates were incubated with 100 µl capture antibody per well at 4˚C overnight. After appropriate washing by the washing buffer from the kits, 200 µl assay dilution buffer was added per well for blocking at room temperature for 1 h. Serial dilutions of standards and samples were added to each well and were incubated at 4˚C overnight. Avidin-horseradish peroxidase (HRP) was added following incubation with the detection antibody for 30 min at room temperature, and the samples were further incubated at room temperature for another 30 min. Subsequently, the 3,3′,5,5′-tetramethylbenzidine substrate was added, and following incubation for 15 min at room temperature, NH₄SO₄ was added to terminate the reaction and absorbance was measured at 450 nm using an ELISA reader (MTP-800 microplate reader; Corona Electric Co., Ltd., Tokyo, Japan).

Western blotting. According to method described by Laemmli (24) for western blotting, electrophoresis was performed using a vertical slab gel containing 12% polyacrylamide. Lung tissues were ground and lysed with radio-immunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China). The concentration of proteins extracted from lung tissues was determined by Gene Spec III from Hitachi Genetic Systems (MiraiBio Group of Hitachi Solutions America, Ltd., South San Francisco, CA, USA) and 20 µg of protein was loaded per gel lane. Proteins were separated by SDS-PAGE and were then electrophoretically transferred to a supported nitrocellulose membrane (Bio-Rad Laboratories, Inc.) using a Semi-Dry Electrobetter for 90 min at 15 V (Sartorius AG, Göttinigen, Germany) (25). The membrane was then treated with Block Ace™ (4%) at 22˚C for 30 min. The membrane was then incubated with rabbit immunoglobulin (Ig)G anti-ERK1/2 (SABI305560; 1:1,000), and the thermocycling conditions were: Holding stage 95˚C for 30 sec, 1 cycle and cycling stage at 95˚C for 3 sec and 40 cycles at 60˚C for 31 sec. The 30 min electrophoresis with agarose gel with ethidium bromide (Sigma-Aldrich, Merck KGaA). Every experiment was repeated 5 times. As described in reference (20), the image analysis was performed using the Image Lab™ software (version 2.1; Bio-Rad Laboratories, Inc., Hercules, CA, USA). PCR results were analyzed by 2^ΔΔCq method (21).
anti-p-ERK1/2 (SAB4301578; 1:1,000) and anti-β-actin (SAB2100037; 1:1, Sigma-Aldrich; Merck KGaA) in phosphate-buffered saline containing 0.03% Tween 20 at 22˚C for 1 h. Following washing in the same buffer, the membrane was incubated with HRP-conjugated goat anti-rabbit IgG (A0545; 20 ng/ml; Sigma-Aldrich; Merck KGaA) at 22˚C for 30 min. Following further washing, an Enhanced Chemiluminescence Plus Western Blotting Detection system (GE Healthcare Life Sciences, Tokyo, Japan) was used to visualize the blot. ImageJ version 1.48 u (National Institutes of Health) was used for the quantification of western blots.

Statistical analysis. Analyses were performed using SPSS version 19.0 (IBM Corp., Armonk, NY, USA). Results are presented as the mean ± standard deviation. Each experiment was repeated at least three times. Multiple comparisons between groups were performed using one-way analysis of variance and Dunnett’s test. P<0.05 was considered to indicate a statistically significant difference.

Results

Hyperoxia-induced decreases in body weight and increases in lung weight are attenuated by fucoidan. Balb/c mice were ventilated with 100% oxygen, with or without atomization inhalation of fucoidan (100 µg/ml), for 36 h. Hyperoxia significantly reduced mouse body weight and increased relative lung weight, whereas fucoidan reversed the hyperoxia-induced alterations in body weight and relative lung weight. Data are presented as the mean ± standard deviation (n=5-6 per group). **P<0.01, vs. control mice; *P<0.05, **P<0.01, vs. hyperoxia-treated mice.

Hyperoxia-induced inflammatory cell infiltration into the BALF is attenuated by fucoidan. Following ventilation with 100% oxygen, with or without atomization inhalation of fucoidan (100 µg/ml), for 36 h, BALF samples of Balb/c mice were collected. (A) Total cell counts and the number of (B) macrophages, (C) neutrophils and (D) lymphocytes in the BALF were determined on cytocentrifuge slides using a hemocytometer. Hyperoxia significantly increased total cell count, and the number of macrophages, neutrophils and lymphocytes, compared with control mice. The hyperoxia-induced increases in total cell count, and the number of macrophages, neutrophils and lymphocytes, in the BALF were significantly reduced in mice receiving fucoidan. Data are presented as the mean ± standard deviation (n=6 per group). **P<0.01, vs. control mice; *P<0.05, **P<0.01, vs. hyperoxia-treated mice. BALF, bronchoalveolar lavage fluid.

Hyperoxia-induced inflammatory cell infiltration into lung tissue is attenuated by fucoidan. Following ventilation with 100% oxygen, with or without atomization inhalation of fucoidan (100 µg/ml), for 36 h, lung tissue of Balb/c mice was collected. The mRNA expression levels of CD68, F4/80 (macrophage markers) (Fig. 3A), CD64 (neutrophil marker) and CD19 (lymphocyte marker) (Fig. 3B) were detected in the lung tissue samples. The mRNA expression levels of CD68, F4/80, CD64 and CD19 were significantly increased in lung tissue by hyperoxia. Treatment with fucoidan significantly suppressed hyperoxia-induced mRNA expression (P<0.01).
Hyperoxia-induced inflammatory cell infiltration in lung tissue is attenuated by fucoidan. Following ventilation with 100% oxygen, with or without atomization inhalation of fucoidan (100 µg/ml), for 36 h, lung tissue was collected from Balb/c mice. The mRNA expression levels of (A) CD68, F4/80 (macrophage markers), (B) CD64 (neutrophil marker) and CD19 (lymphocyte marker) were detected in the lung tissue samples. The mRNA expression levels of CD68, F4/80, CD64 and CD19 were significantly increased in lung tissue by hyperoxia. Treatment with fucoidan significantly suppressed hyperoxia-induced mRNA expression. Data are presented as the mean ± standard deviation (n=6 per group). #P<0.01, vs. hyperoxia-treated mice. CD, cluster of differentiation.

Figure 3. Hyperoxia-induced inflammatory cell infiltration in lung tissue is attenuated by fucoidan. Following ventilation with 100% oxygen, with or without atomization inhalation of fucoidan (100 µg/ml), for 36 h, lung tissue was collected from Balb/c mice. The mRNA expression levels of (A) CD68, F4/80 (macrophage markers), (B) CD64 (neutrophil marker) and CD19 (lymphocyte marker) were detected in the lung tissue samples. The mRNA expression levels of CD68, F4/80, CD64 and CD19 were significantly increased in lung tissue by hyperoxia. Treatment with fucoidan significantly suppressed hyperoxia-induced mRNA expression. Data are presented as the mean ± standard deviation (n=6 per group). #P<0.01, vs. hyperoxia-treated mice. CD, cluster of differentiation.

Hyperoxia-induced lung morphological alterations are attenuated by fucoidan. Balb/c mice were ventilated with 100% oxygen, with or without atomization inhalation of fucoidan (100 µg/ml), for 36 h. Lung morphological alterations were detected in the (A) control, (B) hyperoxia and (C) fucoidan groups. Hyperoxia increased alveolar wall thickness and induced inflammatory cell infiltration into the lung tissue. Hyperoxia-induced morphological alterations were attenuated by fucoidan treatment (n=3 per group). Magnification, x200.

Figure 4. Hyperoxia-induced lung morphological alterations are attenuated by fucoidan. Balb/c mice were ventilated with 100% oxygen, with or without atomization inhalation of fucoidan (100 µg/ml), for 36 h. Lung morphological alterations were detected in the (A) control, (B) hyperoxia and (C) fucoidan groups. Hyperoxia increased alveolar wall thickness and induced inflammatory cell infiltration into the lung tissue. Hyperoxia-induced morphological alterations were attenuated by fucoidan treatment (n=3 per group). Magnification, x200.

Hyperoxia-induced increases in the expression of inflammatory factors in the BALF and lung tissue are attenuated by fucoidan. Balb/c mice were ventilated with 100% oxygen, with or without atomization inhalation of fucoidan (100 µg/ml), for 36 h. BALF and lung tissue samples were then harvested. The expression levels of IL-1, IL-6 and TNF-α in the BALF (Fig. 5A) and lung tissue (Fig. 5B) were significantly increased by hyperoxia (P<0.01). Hyperoxia-induced increases in the expression levels of IL-1, IL-6 and TNF-α in the BALF and lung tissue were significantly reduced following treatment with fucoidan (P<0.05).

Hyperoxia-induced phosphorylation of ERK1/2 is attenuated by fucoidan. Balb/c mice were ventilated with 100% oxygen, with or without atomization inhalation of fucoidan (100 µg/ml), for 36 h. Lung tissue samples were then harvested. Hyperoxia significantly increased phosphorylation of ERK1/2 in lung tissue (Fig. 6). However, the hyperoxia-induced phosphorylation of ERK1/2 in the lung tissue was significantly reduced following treatment with fucoidan (P<0.01).

Discussion

In recent years, high oxygen mechanical ventilation has been widely used as a clinical therapy to treat various diseases (1), including conditions associated with serious respiratory failure, such as hypoxemia and ARDS (2). However, as suggested in a previous study (3), and clinically (26), exposure to high levels of oxygen for prolonged periods of time may lead to inflammation and lung injury (4). Therefore, a therapeutic strategy that alleviates hyperoxia-induced lung injury is required.

Interest in the biological activities of marine organisms has intensified (9). Fucoidan, which is an extract of the seaweed Fucus vesiculosus, has been widely investigated and has been reported to serve an important role in cancer (10) and inflammation (11). Fucoidan is able to suppress various inflammatory cytokines, including IL-1β, TNF-α, interferon-γ and cyclooxygenase-2 (11). Fucoidan is an antioxidant, anticancer and anti-inflammatory agent (12), which also exerts effects against diabetic nephropathy (13). The present study investigated the protective effects of fucoidan against hyperoxia-induced lung injury. Prior to the present study, we performed a dose-dependent study using 1, 10, 100 and 1,000 µg/ml fucoidan; significant alterations occurred when ≥100 µg/ml fucoidan was used; therefore, 100 µg/ml was used as the standard concentration in the present study.

The present study demonstrated that hyperoxia significantly increased total cell count, and the number of macrophages, neutrophils and lymphocytes in the BALF. In addition, hyperoxia significantly increased the mRNA expression levels of CD68 and F4/80 (macrophage markers), CD64 (neutrophil marker) and CD19 (lymphocyte marker), and induced increases in alveolar wall thickness and inflammatory cell infiltration into the lung tissue. These results are consistent with those of a previous study, which suggested that hyperoxia may recruit inflammatory cells, such as macrophages, lymphocytes and neutrophils (27). Fucoidan significantly reduced hyperoxia-induced inflammatory cell infiltration into the BALF and lung tissue, and attenuated the morphological alterations. Furthermore, normal mice were treated with fucoidan only; no significant differences were detected between the control and fucoidan-treated normal mice (data not shown), strongly indicating that fucoidan did not exhibit cytotoxicity.
High oxygen mechanical ventilation may lead to lung injury, and secretion of chemokines and cytokines, such as IL-1, IL-6 and TNF-α, thus resulting in inflammatory cell infiltration. It has previously been reported that IL-1 and IL-6 are associated with anti- and proinflammatory responses, through the regulation of leukocyte apoptosis and function, and may beneficially regulate neutrophil migration and adhesion (31). Elevated levels of IL-1, IL-6 and TNF-α have been demonstrated as biological markers in numerous models of lung injury (32,33).

To improve understanding regarding hyperoxia-induced lung injury, the expression levels of IL-1, IL-6 and TNF-α in the BALF and lung tissue were examined in the present study. Hyperoxia significantly increased the expression levels of IL-1, IL-6 and TNF-α in the BALF and lung tissue, whereas hyperoxia-induced expression was significantly attenuated in the BALF and lung tissue following treatment with fucoidan.

It has also been demonstrated that activation of the ERK1/2 pathway may be involved in defense signaling against oxidative injury (14). The ERK1/2 pathway is a signaling cascade that is involved in protection from damage, the activation of which is generally hypothesized to mediate cell survival (34). Secretion of chemokines and cytokines, such as IL-1, IL-6 and TNF-α, are associated with the phosphorylation of ERK1/2 (15). To better understand the underlying mechanism, the present study examined the phosphorylation of ERK1/2 (15). To better understand the underlying mechanism, the present study examined the phosphorylation of ERK1/2.

The protective mechanism of fucoidan in hyperoxia-induced lung injury is presented in Fig. 7. Briefly, hyperoxia increased phosphorylation of ERK1/2, increased the expression levels of IL-1, IL-6 and TNF-α, and induced lung morphological alterations and inflammation. Hyperoxia-induced effects were attenuated following treatment with fucoidan. ERK1/2, extracellular signal-regulated kinase 1/2; P-, phosphorylated; IL,- interleukin; TNF-α, tumor necrosis factor-α.
References


